Investors & News

Latest News

December 20, 2019
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
November 19, 2019
Stealth Biotherapeutics to Present at Jefferies 2019 London Healthcare Conference
November 14, 2019
Stealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business Highlights
All News

Stock Quote (MITO)

Share

Why invest?

Our Company

Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.

Our Programs

We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.

Our Pipeline

We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.

Latest Reports

March 14, 2019
6-K Report of Foreign Private Issuer
HTML
February 14, 2019
Stealth BioTherapeutics Prospectus
HTML
Reports

Latest Presentations

January 15, 2020
Investor Presentation January 2020
Presentations

Events

December 20, 2019
Stealth BioTherapeutics Inc. Conference Call Webcast
Webcast
November 20, 2019
Jefferies London Healthcare Conference
Webcast
Financial Calendar
Media Relations

Amelia Stetler, 617-762-2562
media@stealthbt.com

Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com